Back to Search
Start Over
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
- Source :
-
Blood [Blood] 2004 Nov 15; Vol. 104 (10), pp. 3361-3. Date of Electronic Publication: 2004 Aug 03. - Publication Year :
- 2004
-
Abstract
- To improve the antimyeloma effect of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation in multiple myeloma, we investigated in a phase 1/2 study the effect of low-dose thalidomide (100 mg) followed by DLI in 18 patients with progressive disease or residual disease and prior ineffective DLI after allografting. The overall response rate was 67%, including 22% complete remission. Major toxicity of thalidomide was weakness grade I/II (68%) and peripheral neuropathy grade I/II (28%). Only 2 patients experienced mild grade I acute graft versus host disease (aGvHD) of the skin, while no grades II to IV aGvHD was seen. De novo limited chronic GvHD (cGvHD) was seen in 2 patients (11%). The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease.
- Subjects :
- Adult
Combined Modality Therapy
Graft vs Host Disease epidemiology
Humans
Immunosuppressive Agents adverse effects
Incidence
Middle Aged
Remission Induction
Thalidomide adverse effects
Transplantation, Homologous
Treatment Outcome
Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents administration & dosage
Immunotherapy, Adoptive
Multiple Myeloma drug therapy
Thalidomide administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 0006-4971
- Volume :
- 104
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Academic Journal
- Accession number :
- 15292062
- Full Text :
- https://doi.org/10.1182/blood-2004-05-2031